search
Back to results

A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer

Primary Purpose

Solid Tumors, Head and Neck Cancer

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SYH2051 tablets
Intensity-Modulated Radiation Therapy (IMRT)
Sponsored by
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥18 years old, male or female; Phase Ia: Patients with histologically or cytologically confirmed advanced solid tumors, for whom there is no standard therapy available, or ineffective or intolerant to standard therapy. Phase Ib/Ic: Patients with histologically or cytologically confirmed locally advanced head and neck cancer suitable for radiotherapy alone; Eastern Collaborative Oncology Group (ECOG) Performance Status of 0~1; Patients in medical conditions to be able to receive radiotherapy (for phase Ib/Ic); Life expectancy of >3 months; At least one measurable lesion (excluding patients in phase Ic combined with adjuvant radiotherapy); Patients with adequate hematologic, hepatic, renal and coagulation function; Patients are not pregnant or lactating and required contraception; Patients who are willing to provide written informed consent form (ICF) before the beginning of the study. Exclusion Criteria: Any antineoplastic therapy such as chemotherapy, biologic therapy, endocrine therapy, or immunotherapy within 4 weeks before the first dose of the study drug (or within 5 half-lives of other unmarketed study drugs, whichever is longer), except for the following: 6 weeks for Nitrosoureas or mitomycin C; 2 weeks or five half-lives (whichever is longer) for oral fluorouracil and small molecule targeted drugs; 2 weeks for Chinese herbal medicine with antineoplastic indications; Patients with previous (within 2 years before screening) or concurrent other malignancies (only for phase Ib/Ic); Patients had undergone major organ surgery (excluding needle biopsies) within 4 weeks before the first dose, with obvious trauma, or require elective surgery during the study; Severe, non-healing fractures within 4 weeks before the first dose of the study drug; The adverse reactions of previous antineoplastic therapy have not recovered to ≤grade 1 as determined by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria; Patients who had received treatment with any drug that is a medium or strong inhibitor or inducer of cytochrome P450 (CYP) 3A4/5 enzyme activity within 2 weeks before screening or need to continue receiving such drugs; Active brain metastases and/or carcinomatous meningitis; Concurrent serious and/or uncontrolled medical conditions at screening (e.g., severe chronic obstructive pulmonary disease); History of severe cardiovascular disease; History of myopathy or raised creatine kinase (CK) >5 times the upper limit of normal (ULN); Known hypersensitivity or intolerance to any component of the study drug or its excipients; History of autoimmune disease, immunodeficiency disease, including HIV testing positive or other acquired, congenital immunodeficiency diseases, or organ transplantation; Active hepatitis B virus, hepatitis C virus or active syphilis infection; Active dysphagia, malabsorption or other chronic gastrointestinal diseases or conditions that may hamper compliance and/or absorption of the study drug; Other ineligibilities according to the investigator.

Sites / Locations

  • Clinical Trials Information GroupRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Arm A: SYH2051 monotherapy dose escalation in advanced solid tumors (Phase Ia)

Arm B: SYH2051+RT dose escalation in locally advanced head and neck cancer (Phase Ib)

Arm C: SYH2051+RT dose expansion in locally advanced head and neck cancer (Phase Ic)

Arm Description

Outcomes

Primary Outcome Measures

Incidence of dose-limiting toxicities (DLTs)
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Maximum tolerated dose (MTD)(if any) or maximum administrated dose (MAD)
Recommended phase 2 dose (RP2D) of SYH2051 in combination with RT

Secondary Outcome Measures

Phase Ia: Maximum Plasma Concentration (Cmax)
Phase Ia: Time to Maximum Plasma Concentration (Tmax)
Phase Ia: Area under the plasma concentration-time curve from time zero to time of last measurable concentration(AUC0-last)
Phase Ia: Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)
Objective response rate (ORR)
Disease Control Rate (DCR)
Duration of locoregional control (DoLC)
Phase Ib and Ic: Concentrations of SYH2051

Full Information

First Posted
August 14, 2023
Last Updated
August 21, 2023
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT06011291
Brief Title
A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer
Official Title
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYH2051 Monotherapy in Patients With Advanced Solid Tumors or in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 15, 2023 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
August 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with radiotherapy (RT) in patients with locally advanced head and neck cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors, Head and Neck Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
73 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A: SYH2051 monotherapy dose escalation in advanced solid tumors (Phase Ia)
Arm Type
Experimental
Arm Title
Arm B: SYH2051+RT dose escalation in locally advanced head and neck cancer (Phase Ib)
Arm Type
Experimental
Arm Title
Arm C: SYH2051+RT dose expansion in locally advanced head and neck cancer (Phase Ic)
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
SYH2051 tablets
Intervention Description
Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
Intervention Type
Radiation
Intervention Name(s)
Intensity-Modulated Radiation Therapy (IMRT)
Intervention Description
Radical or adjuvant radiotherapy
Primary Outcome Measure Information:
Title
Incidence of dose-limiting toxicities (DLTs)
Time Frame
31 days for Arm A and 11 weeks for Arm B
Title
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame
2 years
Title
Maximum tolerated dose (MTD)(if any) or maximum administrated dose (MAD)
Time Frame
up to 1 year
Title
Recommended phase 2 dose (RP2D) of SYH2051 in combination with RT
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Phase Ia: Maximum Plasma Concentration (Cmax)
Time Frame
1 years
Title
Phase Ia: Time to Maximum Plasma Concentration (Tmax)
Time Frame
1 years
Title
Phase Ia: Area under the plasma concentration-time curve from time zero to time of last measurable concentration(AUC0-last)
Time Frame
1 years
Title
Phase Ia: Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)
Time Frame
1 years
Title
Objective response rate (ORR)
Time Frame
2 years
Title
Disease Control Rate (DCR)
Time Frame
2 years
Title
Duration of locoregional control (DoLC)
Time Frame
2 years
Title
Phase Ib and Ic: Concentrations of SYH2051
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old, male or female; Phase Ia: Patients with histologically or cytologically confirmed advanced solid tumors, for whom there is no standard therapy available, or ineffective or intolerant to standard therapy. Phase Ib/Ic: Patients with histologically or cytologically confirmed locally advanced head and neck cancer suitable for radiotherapy alone; Eastern Collaborative Oncology Group (ECOG) Performance Status of 0~1; Patients in medical conditions to be able to receive radiotherapy (for phase Ib/Ic); Life expectancy of >3 months; At least one measurable lesion (excluding patients in phase Ic combined with adjuvant radiotherapy); Patients with adequate hematologic, hepatic, renal and coagulation function; Patients are not pregnant or lactating and required contraception; Patients who are willing to provide written informed consent form (ICF) before the beginning of the study. Exclusion Criteria: Any antineoplastic therapy such as chemotherapy, biologic therapy, endocrine therapy, or immunotherapy within 4 weeks before the first dose of the study drug (or within 5 half-lives of other unmarketed study drugs, whichever is longer), except for the following: 6 weeks for Nitrosoureas or mitomycin C; 2 weeks or five half-lives (whichever is longer) for oral fluorouracil and small molecule targeted drugs; 2 weeks for Chinese herbal medicine with antineoplastic indications; Patients with previous (within 2 years before screening) or concurrent other malignancies (only for phase Ib/Ic); Patients had undergone major organ surgery (excluding needle biopsies) within 4 weeks before the first dose, with obvious trauma, or require elective surgery during the study; Severe, non-healing fractures within 4 weeks before the first dose of the study drug; The adverse reactions of previous antineoplastic therapy have not recovered to ≤grade 1 as determined by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria; Patients who had received treatment with any drug that is a medium or strong inhibitor or inducer of cytochrome P450 (CYP) 3A4/5 enzyme activity within 2 weeks before screening or need to continue receiving such drugs; Active brain metastases and/or carcinomatous meningitis; Concurrent serious and/or uncontrolled medical conditions at screening (e.g., severe chronic obstructive pulmonary disease); History of severe cardiovascular disease; History of myopathy or raised creatine kinase (CK) >5 times the upper limit of normal (ULN); Known hypersensitivity or intolerance to any component of the study drug or its excipients; History of autoimmune disease, immunodeficiency disease, including HIV testing positive or other acquired, congenital immunodeficiency diseases, or organ transplantation; Active hepatitis B virus, hepatitis C virus or active syphilis infection; Active dysphagia, malabsorption or other chronic gastrointestinal diseases or conditions that may hamper compliance and/or absorption of the study drug; Other ineligibilities according to the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Trials Information Group officer
Phone
86-0311-69085587
Email
ctr-contact@cspc.cn
Facility Information:
Facility Name
Clinical Trials Information Group
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clinical Trials Information Group officer
Phone
86-0311-69085587
Email
ctr-contact@cspc.cn

12. IPD Sharing Statement

Learn more about this trial

A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer

We'll reach out to this number within 24 hrs